Latest Medicinal Cannabis News

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

ECS Botanics reports a 20% quarterly surge in direct-to-consumer sales and a record medicinal cannabis harvest, supported by an expanded loan facility to fuel further growth.

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.

ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.

Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.

Cann Group Limited has resolved its legal dispute with Rua Biosciences, paving the way for new commercial agreements to supply medicinal cannabis products across Australia and New Zealand.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

ECS Botanics is on track for a record-breaking FY25 harvest with a 50% production increase and new premium product launches, signaling strong growth and a positive cash flow outlook.

Cann Group Limited reported a 20% rise in Q3 production and improved operating cash flow, while navigating a 38% sales dip due to order timing. The company bolstered its balance sheet with new funding and expanded its Botanitech distribution network.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.